Abbott announces new data from its Volt CE Mark Study
Abbott (ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation, PFA, therapy with the Volt PFA System for the treatment of atrial fibrillation. The data also highlights the excellent safety profile of the Volt PFA System alongside the system's ability to achieve results with fewer therapy applications than on-market competitive PFA systems. PFA therapy works differently from traditional cardiac ablation approaches by delivering high energy electrical pulses to targeted areas of cardiac tissue causing abnormal heart rhythms. Abbott designed its Volt CE Mark Study to assess the impact of the Volt PFA System in two different patient groups – people battling paroxysmal atrial fibrillation – episodes that come and go – as well as persistent AFib – episodes that last longer than seven days.
Stay Ahead of the Market:
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
19 hours ago
- Business Insider
Bernstein Keeps Their Buy Rating on Agilon Health (AGL)
In a report released today, Lance Wilkes from Bernstein maintained a Buy rating on Agilon Health (AGL – Research Report), with a price target of $7.50. The company's shares closed today at $2.16. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Humana, and Elevance Health. According to TipRanks, Wilkes has an average return of -0.3% and a 42.86% success rate on recommended stocks. Currently, the analyst consensus on Agilon Health is a Hold with an average price target of $4.60.
Business Insider
a day ago
- Business Insider
Cardinal Health (CAH) Gets a Buy from Mizuho Securities
In a report released today, Steven Valiquette from Mizuho Securities maintained a Buy rating on Cardinal Health (CAH – Research Report), with a price target of $161.00. The company's shares opened today at $153.54. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Valiquette covers the Healthcare sector, focusing on stocks such as Align Tech, Cencora, and DENTSPLY SIRONA. According to TipRanks, Valiquette has an average return of 0.4% and a 54.81% success rate on recommended stocks. Cardinal Health has an analyst consensus of Strong Buy, with a price target consensus of $165.73, a 7.94% upside from current levels. In a report released on June 3, Leerink Partners also reiterated a Buy rating on the stock with a $177.00 price target.
Yahoo
a day ago
- Yahoo
Texas reined in recreational THC for more medical marijuana this legislative session
Texas lawmakers this year heavily focused their drug policy agenda on banning tetrahydrocannabinol, or THC, products in the state. Senate Bill 3, which prohibits the possession of consumable hemp products that contain any synthetic cannabinoid, often known as delta-8, was a priority for Lt. Gov. Dan Patrick, who often denounced the effects of the drug on children. As a concession of sorts to veterans and THC users with chronic conditions, House Bill 46 also passed, expanding the state's medical marijuana program by providing more products to users and adding more qualifying conditions. Both bills found themselves tied together as lawmakers reasoned that removing hemp options from the general public could be offset by expanding the medical marijuana industry. While the focus was primarily on THC this session, Texas quietly passed Senate Bill 2308, which would create a state-funded consortium to research a psychedelic drug called ibogaine. The clinical trials would test whether ibogaine is a viable treatment for substance use disorders and other mental health conditions. However, multiple bills that could have prevented overdose deaths failed to gain traction this year. House Bill 1644, for example, would have removed testing strips for fentanyl and xylazine, a veterinary sedative also known as 'tranq,' from the list of banned drug paraphernalia. In 2019, Texas lawmakers embraced the potential to boost the state's agricultural market by legalizing hemp products derived from cannabis plants with less than 0.3% of THC. Six years later, SB 3 intends to shut down the $8 billion hemp industry and cut its estimated 50,000 jobs when the ban takes effect in September. Critics say the hemp industry has exploited a loophole in the 2019 law to the tune of more than 8,000 retailers now selling THC-laced edibles, drinks, vapes, and flower buds. The proposed law would ban consumable hemp products that contain any synthetic cannabinoid, often known as delta-8. Non-intoxicating and non-psychoactive CBD or CBG would remain legal. People found in possession of a product with those intoxicating cannabis compounds could face a fine of up to $500. Higher fines and jail time would be possible for repeat offenders. Hemp industry leaders and advocates have denied any harmful intentions and are in favor of regulations on the industry rather than a ban. Aging Texans, veterans, and parents of children with mental illness or special needs have spoken out about the benefits of hemp, including the ease of access, the variety of products available to them, and the lower price. In contrast, concerned parents demanded a ban because they fear children would be harmed from recreational use. The Texas Hemp Business Council reported that it delivered 5,000 letters to Abbott's office earlier this week, along with a petition signed by over 120,000 people, urging the governor to veto the bill. Abbott has until June 22 to decide on a veto. In Texas, licensed medical cannabis providers must house all operations — including cannabis cultivation, processing, extracting, manufacturing, testing, and dispensing — under one roof. State regulations also prohibit inventory storage of medical cannabis products in multiple locations, so products must be distributed from the central dispensary. Any prescriptions scheduled for pickup outside the central dispensary must be driven daily to and from the pickup location — sometimes hundreds of miles round-trip. This has made their products more expensive and limited where the medical marijuana program can reach, hampering the small medical cannabis market in Texas. HB 46 aims to help by expanding the program to include more popular products such as prescribed inhalers and vaping devices, allow off-site storage and add nine dispensers, bringing the total to 12. It also adds traumatic brain injuries, chronic pain, Crohn's disease, and terminal illnesses to the list of qualifying conditions. The first three dispensers will be selected from the previously submitted 2015 list of dispensers and then made available to the public. The expansion of the medical marijuana program will go into effect in September if Abbott signs it into law. Among drug-related bills that received less attention was SB 2308, which will make Texas a hub for ibogaine-related research, development, treatment, manufacturing, and distribution. This will be accomplished by creating a consortium that includes higher education institutions, drug developers, nonprofits, and other stakeholders to secure U.S. Food and Drug Administration approval for a treatment. Ibogaine is a psychedelic found in the roots of the iboga plant, primarily found in Africa, and has been used for centuries during shamanistic rituals due to its ability to induce hallucinations in large doses. The drug has been illegal in many countries, but scientists recently announced a study finding that, in low doses, ibogaine might have beneficial uses to treat addiction, PTSD, and brain injuries. The bill could essentially give Texas a stake in any future revenue that may come from the state developing a medical use for ibogaine. The program will be funded through a $50 million appropriation from the state's general fund. Fentanyl, a potent drug commonly mixed with other substances and has caused the deaths of more than 7,000 Texans in the last six years, is odorless and tasteless, making detection nearly impossible without specialized equipment. Fentanyl test strips are among the cheapest and easiest ways to prevent overdoses, but for a third time, legislation to legalize them failed in the Senate. HB 1644, which would have legalized opioid drug testing strips, never got a hearing in the Senate despite passing unanimously in the House. The main argument against drug testing strips has been that it encourages continued drug use, but advocates deny this claim, saying that once someone is thinking about their safety, it is by the time they are getting close to quitting. Senate Bill 1732, which would have allowed nurses and physician assistants to prescribe medication-assisted treatment, like methadone and buprenorphine, for opioid use disorders, also never received a committee hearing. A smaller step lawmakers made to address overdoses comes in House Bill 4783, which requires the Texas Health and Human Services Commission to prepare a report every two years for lawmakers to evaluate the distribution of opioid overdose reversal drugs, like Narcan. The report will be required to create a statewide goal for opioid reversal drugs and include an estimate of insufficiencies in the current supply and a plan to address overdoses in high-risk areas.
